Researchers have built a highly sensitive, light‑driven sensor that can pick up trace amounts of cancer‑related molecules in a simple blood draw. The technology could enable doctors to spot early warning signs of malignancy long before imaging methods reveal a tumor.
In the earliest stages of disease, biomarkers—tiny proteins, DNA fragments or other molecular signatures—appear at concentrations that are barely detectable with standard assays. By integrating DNA‑shaped nanostructures, quantum dots and CRISPR‑Cas12a editing tools, the new platform translates these faint signals into a clear optical readout using a phenomenon called second‑harmonic generation (SHG).
The work, published in Optica, demonstrates that the sensor can identify lung‑cancer markers in patient serum at sub‑attomolar levels. Because the system is programmable, it could be retuned to recognize viral particles, bacterial toxins or markers linked to neurodegenerative disorders such as Alzheimer's disease.
"With this approach we envision routine blood screens that flag lung cancer well before a nodule becomes visible on a CT scan," the team leader explained. "Continuous monitoring of biomarker levels could also help clinicians gauge how a therapy is working, shortening the time between treatment decisions and imaging confirmation."
Amplification‑Free Optical Sensing
Most current tests rely on chemical amplification steps that add cost, time and complexity. The new device skips those stages entirely. SHG occurs when incoming photons are converted into new photons with half the original wavelength, producing a signal with very low background noise.
In this design, SHG is generated on the surface of a two‑dimensional semiconductor—molybdenum disulfide (MoS₂). DNA tetrahedrons act as nanoscopic scaffolds, positioning quantum dots at exact distances from the MoS₂ layer. The dots boost the local electric field, amplifying the SHG signal without any chemical reagents.
CRISPR‑Cas12a is incorporated as a molecular recognizer. When the Cas12a protein binds its target biomarker, it cleaves the DNA strands that hold the quantum dots, causing an abrupt drop in SHG intensity. This on‑off switch delivers a highly specific readout that can discriminate a single disease‑related molecule from closely related sequences.
Human Serum Validation
To prove real‑world applicability, the researchers focused on miR‑21, a microRNA heavily associated with lung cancer. After confirming detection in buffered samples, they tested the sensor with serum from diagnosed patients. The device recognized miR‑21 with high fidelity while ignoring other similar RNA fragments.
The next milestone is miniaturization. By shrinking the optical components, the team hopes to create a portable, bedside unit that could be deployed in community clinics or remote settings where conventional laboratory infrastructure is lacking.